1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
Holly LaFon
Articles (8902)  | Author's Website |

Bernard Horn Comments on Teva Pharmaceutical

Guru stock highlight

April 16, 2018 | About:
Teva Pharmaceutical (NYSE:TEVA) continued to face headwinds, with sluggish generic product introductions and pricing pressures. With a new CEO at the helm, Teva launched a comprehensive restructuring plan to shore up its balance sheet. The company enacted layoffs and plant closures, optimized its generics portfolio and reviewed of its R&D and drug pipeline. Consistent with this agenda, Teva announced the termination of its CGRP migraine drug discovery and development pact with Sosei. The company also renegotiated some of its debt at much higher interest rates than previous. Neither of these actions was well received by the market.

From Bernard Horn (Trades, Portfolio)'s first quarter 2018 shareholder letter.

About the author:

Holly LaFon
I'm a financial journalist with a master of science in journalism from Medill at Northwestern University.

Visit Holly LaFon's Website


Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:


Performances of the stocks mentioned by Holly LaFon


User Generated Screeners


blovedayBest Backtest Results
muhua.huangmaster
mathew94Penny
mathew94Earning1Month
ralphdQuality Growth
salvatore34stock screener 2.0
DBrizanall 19SEP2018 942P
HOLKLSUEquity Income 2018 Q3 Energy a
althekear4+%20star,%20dividend%20champs
althekearQuality%20Growth
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK